The development of a manifold single pharmacological agent like tirzepatide that has the ability to significantly lower glucose levels, as well as improve insulin sensitivity, reduce weight and amend dyslipidemia at an early clinical stage is enormously important. This evidence concerns the gene INS and metabolic syndrome.